Taken together, these results suggest that ouabain mediates epigenetic regulation for the treatment of DLBCL through the effects of the m6A demethylase ALKBH5 and the m6A-binding protein IGF2BP2, which can be used as novel biomarkers for the diagnosis of DLBCL. The gene discussed is IGF2BP2; the disease is diffuse large B-cell lymphoma.